Delivery Order SPE2DB22D1017-SPE2DB25FG3CS

Award Date 5/21/25
Potential Completion Date 5/22/25
Potential Value $9.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,390.54, is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product. The contract is a firm fixed-price delivery order, with an ultimate completion date of April 28, 2025. The contract is not set-aside and was awarded on April 25, 2025. AmerisourceBergen Drug Corp holds a significant...
This is a delivery order federal contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of GARDASIL 9 SYRINGE 0.5ML. The contract has a firm fixed price of $9,028.12 and a completion date of May 13, 2025. Amerisourcebergen Drug Corp is the prime contractor, and the contract is not set-aside. The company holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $11,252.15, is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 11, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a firm fixed price of $5,800.41 and a completion date of May 22, 2025. The contract is not set aside and is an open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a ceiling value of $9,995.66. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 30, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $3,286.45, is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product. The contract is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of April 17, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of GARDASIL 9 syringes. The contract has a firm fixed price of $17,474.70 and a completion date of May 13, 2025. The contract is not set aside and allows for the delivery of brand-name and generic pharmaceutical products to support military and government healthcare programs. AmerisourceBergen Drug Corp holds a $999,999,999.00...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,000.50, is for the procurement of GARDASIL 9 SYRINGE 0.5ML, a vaccine product. The contract is a firm fixed-price delivery order, with a period of performance through March 27, 2025. The contract was not set aside for any specific business category. AmerisourceBergen Drug Corp holds a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of GARDASIL 9 SYRINGE 0.5ML, a vaccine product. The contract has a ceiling value of $8,992.59 and a period of performance ending on April 23, 2025. It is a firm fixed-price contract with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a substantial Indefinite Delivery Contract...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of GARDASIL 9 SYRINGE 0.5ML. The contract has a Firm Fixed Price pricing type and a ceiling value of $2,172.35. The contract has an ultimate completion date of April 2, 2025. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB25FG3CS
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a pharmaceutical product. The contract has a firm fixed price of $9,437.33 and a period of performance ending on May 22, 2025. The contract is not set aside and was awarded on May 21, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. This IDC enables the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard.

Generated 8/20/25, 9:59 AM